Get 20% Free Customization In This Report

Buy this report from - $3456

Imatinib Drug Market by Application (Aggressive Systemic Mastocytosis (ASM), Chronic Eosinophilic Leukemia (CEL), Dermatofibrosarcoma Protuberans (DFSP), Gastrointestinal Stromal Tumors (GIST), Hyper-eosinophilic Syndrome (HES), Myelodysplastic Syndrome (MDS), Myeloproliferative Diseases (MPD), Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL), and Philadelphia Chromosome-positive Chronic Myeloid Leukemia (Ph+ CML)) and Drug Formulation (Tablets and Capsules) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Medical Devices & Supplies	LI_182648	Pages: NA	Jun 2018 \| 853 Views
Author's : NA	Tables: NA	Charts: NA	Formats*:

Imatinib is a chemotherapy drug that acts by reducing or preventing the progression of cancer cells. This drug is used for the treatment of certain cancers such as chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal tumors, certain skin tumors (dermatofibrosarcoma protuberans), and myelodysplastic/myeloproliferative diseases.

Growth in prevalence of cancer, increase in demand for target drug therapy, and patent expiry of imatinib drug are expected to drive the imatinib drug market. According to the National Cancer Institute, in June 2017, it was estimated that there will be around 62,130 and 24,500 people with new cases and death due to leukemia, respectively, in the U.S.

Furthermore, rise in healthcare expenditure and increase in awareness of cancer by government and private organizations are anticipated to boost the market growth. In addition, R&D activities related to imatinib are anticipated to present new opportunities during the forecast period. However, high cost of imatinib; adverse effects; presence of substitutes, such as sprycel, tarceva, and tasigna; and stringent government regulations may hinder the market growth.

The imatinib drug market is segmented on the basis of application, drug formulation, and geography. Based on application, it is divided into aggressive systemic mastocytosis (ASM), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST), hyper-eosinophilic syndrome (HES), myelodysplastic syndrome (MDS), myeloproliferative diseases (MPD), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Based on the drug formulation, the market is bifurcated into tablets and capsules. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

The study provides an in-depth analysis of the global imatinib drug market, with current trends and future estimations to elucidate the investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
The report presents a quantitative analysis to help the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of different segments facilitates to understand various products of the market.
Key players are profiled and their strategies are analyzed thoroughly to predict the competitive outlook of the market.

Imatinib Drug Market Key Segments:

By Application

Aggressive Systemic Mastocytosis (ASM)
Chronic Eosinophilic Leukemia (CEL)
Dermatofibrosarcoma Protuberans (DFSP)
Gastrointestinal Stromal Tumors (GIST)
Hyper-eosinophilic Syndrome (HES)
Myelodysplastic Syndrome (MDS)
Myeloproliferative Diseases (MPD)
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Philadelphia Chromosome-positive Chronic Myeloid Leukemia (Ph+ CML)

By Drug Formulation

Tablets
Capsules

By Geography

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
LAMEA
- Latin America
- Middle East
- Africa

List of players profiled in the report

Novartis
Glenmark Pharmaceuticals Ltd.
Sun Pharmaceuticals
Actavis Generics
Dr. Reddy's Laboratories
Teva Pharmaceutical Industries Ltd.
Sanofi S.A.
Cipla Inc.
Apotex Inc.
Mylan Pharms Inc.

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 IMATINIB DRUG MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. CHRONIC EOSINOPHILIC LEUKEMIA (CEL)

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. DERMATOFIBROSARCOMA PROTUBERANS (DFSP)

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. GASTROINTESTINAL STROMAL TUMORS (GIST)

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. HYPER-EOSINOPHILIC SYNDROME (HES)

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. MYELODYSPLASTIC SYNDROME (MDS)

4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast

4.8. MYELOPROLIFERATIVE DISEASES (MPD)

4.8.1. Key market trends
4.8.2. Growth factors and opportunities
4.8.3. Market size and forecast

4.9. PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL)

4.9.1. Key market trends
4.9.2. Growth factors and opportunities
4.9.3. Market size and forecast

4.10. PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML)

4.10.1. Key market trends
4.10.2. Growth factors and opportunities
4.10.3. Market size and forecast

Chapter: 5 IMATINIB DRUG MARKET, BY DRUG FORMULATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. TABLET

5.2.1. Market size and forecast

5.3. CAPSULE

5.3.1. Market size and forecast

Chapter: 6 IMATINIB DRUG MARKET, BY GEOGRAPHY

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Imatinib Drug Market by Application
6.2.5. North America Imatinib Drug Market by Drug Formulation

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Imatinib Drug Market by Application
6.3.5. Europe Imatinib Drug Market by Drug Formulation

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. India market size and forecast
6.4.3.4. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Imatinib Drug Market by Application
6.4.5. Asia-Pacific Imatinib Drug Market by Drug Formulation

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Latin America market size and forecast
6.5.3.2. Middle East market size and forecast
6.5.3.3. Africa market size and forecast

6.5.4. LAMEA Imatinib Drug Market by Application
6.5.5. LAMEA Imatinib Drug Market by Drug Formulation

Chapter: 7 COMPANY PROFILES

7.1. NOVARTIS

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. GLENMARK PHARMACEUTICALS LTD.

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. SUN PHARMACEUTICALS

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. ACTAVIS GENERICS

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. DR. REDDY'S LABORATORIES

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. TEVA PHARMACEUTICAL INDUSTRIES LTD.

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. SANOFI S.A.

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. CIPLA INC.

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. APOTEX INC

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. MYLAN PHARMS INC

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.